Rheumatoid arthritis is a bone disease that needs special attention to prevent mild disability such as joint damage or severe disability such as paralysis. Rational treatment is a key to the success of therapy. Irrational rheumatoid arthritis treatment can increase treatment costs and increase morbidity and mortality further so that the selection of appropriate therapy to achieve therapeutic success. Rheumatoid arthritis is an autoimmune disease that causes inflammation and damages bones. Rheumatoid arthritis can occur due to dysregulation of the body's immune system to its systemic manifestations. The purpose of this study is to evaluate the rationality of rheumatoid arthritis treatment in terms of the right indications, right drug, right patient and right dosage in rheumatoid arthritis patients at the outpatient installation RSUD Dr. Moewardi Surakarta in 2018. This type of research is non-experimental with retrospective data collection and using purposive sampling method that recording medical record data and samples taken according to inclusion criteria including outpatients diagnosed with rheumatoid arthritis, receiving treatment for rheumatoid arthritis (DMARD or biological agents, corticosteroids and NSAIDs), complete patient medical record data. Data on the use of rheumatoid arthritis drugs were analyzed descriptively to obtain an overview of the rationality of rheumatoid arthritis drugs in rheumatoid arthritis patients at RSUD. Dr. Moewardi Surakarta in 2018 based on the Indonesian Rheumatology Association 2014, Pharmacotherapy A Pathophysiologic Approach 10th edition, Drug Information Handbook 2009 and the Indonesian National Drug Information. Based on the results of research on 30 patients with rheumatoid arthritis were obtained the right indications (100%), right patients (90%), and in 67 treatments obtained the right drug (100%), and the right dose (83.6%)